Royalty Pharma Plc (RPRX) - News Archive

Royalty Pharma s Ambitious Financial Maneuvers: A Deep Dive into Recent Moves and Their Implications for Shareholder ValueIn a bold attempt to reshape its financial landscape and enhance shareholder value, Royalty Pharm...

Royalty Pharma s Bold Move: A Quest for Growth and Shareholder ValueIn an eye-catching announcement made on January 10, 2025, Royalty Pharma plc (NASDAQ: RPRX) revealed significant plans aimed at reshaping the company s...

Royalty Pharma Boosts Investor Confidence with Dividend Increase Amid Strategic MovesBy Published January 10, 2025NEW YORK In a bid to solidify its commitment to enhancing shareholder value, Royalty Pharma plc (Nasdaq:...

: This article discusses the recent announcement by Royalty Pharma plc regarding its acquisition of a synthetic royalty on U.S. sales of Geron Corporation s RYTELO for $125 million. The financial implications of this ac...

Royalty Pharma Declares Fourth Quarter Dividend Amid Strategic Partnerships and Market FluctuationsNEW YORK, Oct. 11, 2024 Royalty Pharma plc (Nasdaq: RPRX) has announced a fourth-quarter dividend of $0.21 per Class A o...

Royalty Pharmans Strategic Investments and Shareholder Commitment: A Dual Approach to Driving Value in Endocrine Rare Disease SectornnIn the ever-evolving landscape of biopharmaceuticals, strategic partnerships and inve...

Royalty Pharma Declares Third Quarter Dividend: Impact on Share ValueRoyalty Pharma plc, a leading biopharmaceutical company, recently announced a dividend payout for the third quarter of 2024. The board of directors ap...

Royalty Pharma PLC, a leading player in the Major Pharmaceutical Preparations industry, recently announced the pricing of $1.5 billion of senior unsecured notes. The offering, comprised of various notes, signifies the c...

In a major strategic move, Royalty Pharma plc (Nasdaq: RPRX) has recently sealed an agreement to acquire Agios Pharmaceuticals royalty on Servier s revolutionary drug, vorasidenib. The deal, worth an impressive $905 mil...

Royalty Pharma and Cytokinetics Secure Strategic Funding Collaboration to Propel Commercial Launch of Aficamten and Drive Advancements in Cardiovascular ResearchIn a major development that holds great promise for the ph...

As Royalty Pharma plc (Nasdaq: RPRX) continues to expand its portfolio, the recent announcement of acquiring royalties and milestones on frexalimab from ImmuNext, Inc. for $525 million in cash has stirred interest in th...

NEW YORK, April 17, 2024 - Royalty Pharma plc (Nasdaq: RPRX), a leading biopharmaceutical investment company, announced today that its board of directors has approved the payment of a dividend for the second quarter of...

In a move that offers a fresh demonstration of its robust financial health and rewarding commitment to shareholders, global leader in drug royalty acquisitions, Royalty Pharma plc (RPRX), has declared a dividend of $0.2...

In a recent press release, Royalty Pharma PLC announced the declaration of a dividend for the fourth quarter of 2023. The board of directors approved a dividend payment of $0.20 per Class A ordinary share. This article...